Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy Market Set to Transform Cardiac Care Landscape by 2030 | Top key players - Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma.

The Transthyretin Amyloid Cardiomyopathy Market is expected to grow at a CAGR of 31.1 % during the forecast period (2024-2031).

The Transthyretin Amyloid Cardiomyopathy Market, as analyzed by DataM Intelligence, offers a comprehensive industry overview backed by in-depth insights, historical trends, and key statistics. The report dives deep into market dynamics and competitive strategies, profiling major players along with their product portfolios, pricing models, financial performance, growth initiatives, and regional presence.

Unlock exclusive insights with our detailed sample report (Please enter your Corporate Email ID to get priority access) @ https://datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market?sz

The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market involves the diagnosis, treatment, and management of a rare, progressive heart condition caused by amyloid protein deposits in the heart tissue. This disease leads to heart failure and impaired cardiac function. The market includes pharmaceuticals, diagnostics, and emerging therapies aimed at improving patient outcomes and quality of life.

Major players in the Transthyretin Amyloid Cardiomyopathy Market

The prominent players in Transthyretin Amyloid Cardiomyopathy market research report are: Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma, Alnylam Pharmaceuticals, Prothena Corporation, Regeneron Pharmaceuticals, Corino Therapeutics, Arcturus Therapeutics and Proclara Biosciences.

The companies are primarily focusing on strategies such as new product launches to penetrate the fastest-growing emerging markets across the world.

Key Development

In February 2020, the European Commission approved VYNDAQEL, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM). VYNDAQEL is an oral capsule indicated for adult patients with wild-type or hereditary transthyretin amyloidosis with cardiomyopathy. It comes in two formulations: one for cardiomyopathy and another for stage 1 polyneuropathy.

In December 2021, Ionis Pharmaceuticals partnered with AstraZeneca to develop and commercialize eplontersen, aiming to accelerate market penetration in the growing global TTR amyloidosis market. The companies jointly develop eplontersen in the U.S., while AstraZeneca holds exclusive commercialization rights outside the U.S.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements @ https://datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market

Market Segments

By Treatment Type: Heart Transplantation, Liver Transplantation.

By Medication Type: Tafamidis meglumine, Tafamidis, RNAi therapy, Diuretics, Beta-blockers, Digoxin.

By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

The Transthyretin Amyloid Cardiomyopathy industry is experiencing rapid growth, driven by advancements in medical technologies, increased demand for innovative therapies, and a rising focus on patient-centered care. As these sectors evolve, the need for comprehensive market analysis becomes crucial to understand trends, regulatory changes, and emerging opportunities.

Regions Covered:

The global Transthyretin Amyloid Cardiomyopathy Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.

☞ North America - US, Canada, Mexico

☞ Europe- Germany, Russia, UK, France, Italy, Rest of Europe

☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific

☞ South America- Brazil, Argentina, Colombia, Rest of South America

☞ Middle East and Africa- Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Israel

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.